

### DISEASE BURDEN

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

### CLINICAL RELEVANCE

MK-8527 is a new NRTTI (nucleoside reverse transcriptase translocation inhibitor). Phase 1 results on its antiviral activity were presented at CROI 2024. MK-8527 is developed to be administered orally on a weekly basis.

### INTELLECTUAL PROPERTY LANDSCAPE

MK-8527 primary patents with an expected expiry in 2034 have been granted to MSD in at least 35 LMICs and are pending in another 13. Secondary patent filings are to be expected.

**MK-8527**  
HIV  
TREATMENT  
MSD

### SERVICE DELIVERY ENABLERS

Assessment in progress

### REGULATORY

Assessment in progress

### MANUFACTURING

Assessment in progress

### MARKET

Assessment in progress